Amgen Launches AmgenNow Program to Offer Repatha at Reduced Prices
Amgen has officially launched a new program named AmgenNow, aimed at delivering their innovative cholesterol-lowering medication, Repatha (evolocumab), directly to patients across the United States. This comes after encouraging results from the VESALIUS-CV Phase 3 clinical trial, which showed that Repatha significantly reduces the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart issues. By offering Repatha through this direct-to-patient initiative, Amgen is taking a notable step to ensure that more Americans can access this important medication at a drastically reduced price.
Starting today, eligible patients can obtain Repatha via AmgenNow at a reduced monthly cost of $239, which is nearly 60% lower than the current list price in the United States. This initiative aligns with recent efforts by the government to make prescription medications more affordable for citizens. AmgenNow will be available to all individuals, including those who may not have insurance or are enrolled in high-deductible health plans, as well as those who prefer to pay directly out of pocket.
Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen, highlighted the company’s commitment to improving patient accessibility to essential medications through innovative programs like AmgenNow. He stated, "This program will allow even more Americans at increased risk of major cardiovascular events to benefit from Repatha, which has already aided over 5 million patients."
The launch of AmgenNow signifies a pivotal change in how patients can access life-changing medication. The initiative will enable patients who utilize this program to bypass traditional insurance restrictions, such as prior authorization or step therapy. This is particularly beneficial for those individuals who require immediate access to treatment without the barriers usually posed by the insurance approval process. According to the plan, AmgenNow will be accessible via the TrumpRx website, making it easier for patients to learn how they can enroll.
Repatha itself is a PCSK9 inhibitor, a medication that functions by blocking a protein that leads to LDL cholesterol breakdown in the liver. This mechanism significantly increases the number of LDL receptors available to clear LDL from the bloodstream, thus contributing to lower cholesterol levels. Over the past 15 years, the clinical safety and efficacy of Repatha have been demonstrated in over 50 clinical trials, encompassing more than 57,000 patients worldwide.
The approval of Repatha extends across over 74 countries, including major markets such as the U.S., Japan, and Canada, which speaks to its wide acceptance and acknowledgment in the medical community. Moreover, the potential benefits of this therapy are significant for those with familial hypercholesterolemia or at high cardiovascular risk. For those exploring this new avenue of access, further details are available on the dedicated website for patient support.
While AmgenNow is a step forward for patient access, it is crucial for users of Repatha to remain informed about potential side effects, which can include hypersensitivity reactions and mild to moderate adverse effects such as upper respiratory infections or localized injection site issues. The safety profile has been well-studied, and patients should discuss any concerns with their healthcare providers.
In conclusion, Amgen’s launch of the AmgenNow program holds the promise of increased affordability and accessibility for Repatha, potentially transforming the landscape of treatment for individuals at risk of cardiovascular events. With this approach, Amgen not only supports government measures to lower drug prices but also shows its commitment to patient wellbeing, marking an important milestone in the healthcare industry.
For more information about the AmgenNow program and how to access Repatha, you can visit their official website at www.amgensupportplus.com/patient/repatha for assistance and further details.
Starting today, eligible patients can obtain Repatha via AmgenNow at a reduced monthly cost of $239, which is nearly 60% lower than the current list price in the United States. This initiative aligns with recent efforts by the government to make prescription medications more affordable for citizens. AmgenNow will be available to all individuals, including those who may not have insurance or are enrolled in high-deductible health plans, as well as those who prefer to pay directly out of pocket.
Murdo Gordon, Executive Vice President of Global Commercial Operations at Amgen, highlighted the company’s commitment to improving patient accessibility to essential medications through innovative programs like AmgenNow. He stated, "This program will allow even more Americans at increased risk of major cardiovascular events to benefit from Repatha, which has already aided over 5 million patients."
The launch of AmgenNow signifies a pivotal change in how patients can access life-changing medication. The initiative will enable patients who utilize this program to bypass traditional insurance restrictions, such as prior authorization or step therapy. This is particularly beneficial for those individuals who require immediate access to treatment without the barriers usually posed by the insurance approval process. According to the plan, AmgenNow will be accessible via the TrumpRx website, making it easier for patients to learn how they can enroll.
Repatha itself is a PCSK9 inhibitor, a medication that functions by blocking a protein that leads to LDL cholesterol breakdown in the liver. This mechanism significantly increases the number of LDL receptors available to clear LDL from the bloodstream, thus contributing to lower cholesterol levels. Over the past 15 years, the clinical safety and efficacy of Repatha have been demonstrated in over 50 clinical trials, encompassing more than 57,000 patients worldwide.
The approval of Repatha extends across over 74 countries, including major markets such as the U.S., Japan, and Canada, which speaks to its wide acceptance and acknowledgment in the medical community. Moreover, the potential benefits of this therapy are significant for those with familial hypercholesterolemia or at high cardiovascular risk. For those exploring this new avenue of access, further details are available on the dedicated website for patient support.
While AmgenNow is a step forward for patient access, it is crucial for users of Repatha to remain informed about potential side effects, which can include hypersensitivity reactions and mild to moderate adverse effects such as upper respiratory infections or localized injection site issues. The safety profile has been well-studied, and patients should discuss any concerns with their healthcare providers.
In conclusion, Amgen’s launch of the AmgenNow program holds the promise of increased affordability and accessibility for Repatha, potentially transforming the landscape of treatment for individuals at risk of cardiovascular events. With this approach, Amgen not only supports government measures to lower drug prices but also shows its commitment to patient wellbeing, marking an important milestone in the healthcare industry.
For more information about the AmgenNow program and how to access Repatha, you can visit their official website at www.amgensupportplus.com/patient/repatha for assistance and further details.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.